Amore 1989.

Methods	Four‐week double blind, randomised study.
Participants	Psychiatric inpatients meeting DSM‐III for major depression without psychotic features, with a minimum baseline score of 21 on the HDRS‐21. Age range: 20‐70 years old. Exclusion criteria: during pregnancy, lactation, or being of childbearing potential, serious diseases, alcohol or drug abuse, or treatment with any medications that might interact with antidepressant drugs.
Interventions	Fluvoxamine: 15 participants. Imipramine: 15 participants. Fluvoxamine dose range: 100‐150 mg/day. Imipramine dose range: 100‐150 mg/day. Benzodiazepine were allowed as additional medications.
Outcomes	Hamilton Rating Scale for Depression (HRSD) ‐21, Zung Self‐Rating Depression Scale, Clinical Global Impression‐severity (CGI‐S) and Clinical Global Impression‐improvement (CGI‐I). Total dropout, dropout due to inefficiency, due to side effects, side effect profile.
Funded by pharmaceutical companies	Funded by pharmaceutical company markets fluvoxamine.
Fluvoxamine as an investigational or comparator drug	As an investigational drug.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "randomly assigned", no further details.
Allocation concealment (selection bias)	Unclear risk	No details.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Quote: "in a double blind fashion", no further details.
Incomplete outcome data (attrition bias) All outcomes	High risk	Study endpoint: 5/15 missing from control group (4 due to adverse effects).
Selective reporting (reporting bias)	High risk	Standard deviations (SDs) of endpoint / change score for depression were not reported.